• Merck flagged late-stage updates across its oncology portfolio scheduled for presentation at ASCO 2026, led by long-term follow-up from KEYNOTE-942 testing individualized neoantigen therapy intismeran autogene with Keytruda in resected high-risk melanoma.
• Company also pointed to final analysis from Phase 3 KEYNOTE-522, with results described as sustaining a survival advantage for Keytruda with chemotherapy in high-risk early-stage triple-negative breast cancer.
• In lung cancer, Phase 3 OptiTROP-Lung05 data in China will outline how investigational TROP2 antibody-drug conjugate sacituzumab tirumotecan performed with pembrolizumab as first-line therapy for PD-L1-positive advanced non-small cell lung cancer.
• ASCO press program will feature ASCENT-04/KEYNOTE-D19, with Merck highlighting progression-free survival findings for pembrolizumab with Trodelvy in previously untreated PD-L1-positive metastatic triple-negative breast cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605120645BIZWIRE_USPR_____20260512_BW451666) on May 12, 2026, and is solely responsible for the information contained therein.